-

908 Devices to Participate in the Gilmartin Group Emerging Growth Company Showcase

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the upcoming Gilmartin Group Emerging Growth Company Showcase.

908 Devices’ management is scheduled to present on Thursday, September 21 at 9:00 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.908devices.com.

About 908 Devices

908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic sampling and separations, software automation, and machine learning.

Forward Looking Statements

This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the Company’s future revenue and growth. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC's website at www.sec.gov. Additional information will be made available in our annual and quarterly reports and other filings that we make from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

Contacts

Media Contact
Barbara Russo
brusso@908devices.com

Investor Contact
Carrie Mendivil
IR@908devices.com

908 Devices Inc.

NASDAQ:MASS

Release Versions

Contacts

Media Contact
Barbara Russo
brusso@908devices.com

Investor Contact
Carrie Mendivil
IR@908devices.com

More News From 908 Devices Inc.

908 Devices Launches VipIR, a 3-in-1 Handheld Analyzer for Field-Based Chemical Identification of Unknown Bulk Substances

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces the launch of VipIR, a 3-in-1 handheld analyzer that sets a new standard for rapid and confident field-based chemical identification of unknown bulk solids and liquids, such as narcotics, explosives, and toxic chemicals. VipIR enables customs and border personnel and hazardous response teams to simplify workflows and eliminate guesswork, accelerating decision ma...

908 Devices Appoints Christopher D. Brown to its Board of Directors

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (Nasdaq: RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company’s Chief Technology Officer & Vice President of Research & Development from February 2...

Metropolitan Washington Council of Governments Adds 908 Devices’ XplorIR to Its Hazardous Materials Response Toolkit

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that the Metropolitan Washington Council of Governments (COG) has purchased eight XplorIR devices, one for each of the seven counties and District of Columbia, which comprise the COG. The devices were shipped in Q1 2025, with training taking place in Q2 2025. The handheld XplorIR device accurately detects, identifies, and quantifies 5,000 unknown gas and vapor c...
Back to Newsroom